Board member Jack Bech Nielsen resigns for health reasons; subsidiary Zynerba renamed

Harmony Biosciences Holdings, Inc.

Jack Bech Nielsen resigned from the Board effective June 27, 2024 due to health reasons; no disagreements with the company.
Wholly owned subsidiary Zynerba Pharmaceuticals, Inc. renamed to Harmony Biosciences Management, Inc. effective July 1, 2024.
No financial or operational impact disclosed from either event.
Ticker: HRMY.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jack Bech Nielsen

Director

HRMY · Harmony Biosciences Holdings, Inc.

Effective: 2024-06-27
Filed: July 1, 2024, 7:59 PM ET

On June 27, 2024, Jack Bech Nielsen notified the Board of Directors (the “Board”) of Harmony Biosciences Holdings, Inc. (the “Company”) that he is resigning from the Board effective immediately, due to health reasons.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Jack Bech Nielsen resigned as Director at Harmony Biosciences Holdings, Inc..

Action: resigned
Role: Director

Exact text from the filing

On June 27, 2024, Jack Bech Nielsen notified the Board of Directors (the “Board”) of Harmony Biosciences Holdings, Inc. (the “Company”) that he is resigning from the Board effective immediately, due to health reasons.

View on SEC.gov

Harmony Biosciences Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-009642

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.